Sign In
Buy AFMD
$0.182
+0 (+0%)
At Close: Sep 16, 2025
Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting
12:05pm, Friday, 29'th May 2020
Affimed N.V. (AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today shared details of its AFM13 REDIRECT clinical trial design a
Affimed to Present at the Jefferies Virtual Healthcare Conference
09:00am, Thursday, 28'th May 2020
Heidelberg, Germany, May 28, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight.
Affimed researchers served as co-authors on an abstract for RO7297089 with scientific collaborators from Genentech, a member of the Roche GroupAffimed will host a live.
Downgrade: Here's How Analysts See Affimed N.V. (NASDAQ:AFMD) Performing In The Near Term
12:12pm, Sunday, 03'rd May 2020
Today is shaping up negative for Affimed N.V. (NASDAQ:AFMD) shareholders, with the analysts delivering a substantial...
Earnings Update: Affimed N.V. (NASDAQ:AFMD) Just Reported And Analysts Are Trimming Their Forecasts
12:07pm, Friday, 01'st May 2020
Last week, you might have seen that Affimed N.V. (NASDAQ:AFMD) released its yearly result to the market. The early...
All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy
12:00am, Wednesday, 29'th Apr 2020Affimed N.V. (AFMD) Q4 2019 Earnings Call Transcript
10:31pm, Tuesday, 28'th Apr 2020
This morning, Affimed issued a press release, which is posted on our website at www.affimed.com. On the call today with prepared remarks are Adi Hoess, Chief Executive Officer of Affimed; Andreas Har
Affimed: Q4 Earnings Insights
12:30pm, Tuesday, 28'th Apr 2020
Shares of Affimed (NASDAQ:AFMD) rose 0.9% in pre-market trading after the company reported Q4 results.Quarterly Results Earnings per share decreased 223.53% year over year to ($0.21), which missed the
Affimed Reports 2019 Financial Results and Recent Operational Progress
10:35am, Tuesday, 28'th Apr 2020
AFM24: First patient dosed in first-in-human clinical study for advanced EGFR-expressing solid tumors, including colon, lung and other cancersAFM13: Initiated.
Affimed N.V. (AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the first patient was successfully dosed in a
Affimed Announces First Patient Successfully Dosed in First-in-Human Phase –/—A Study of ...
12:00am, Thursday, 16'th Apr 2020Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020
07:15pm, Monday, 06'th Apr 2020
NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a fourth day of presentations as pa
